We prepared11C-labeled5-(4-chlorophenyl)-l-(4-methoxyphenyl)-3-(trifluoromethyl)-lH-pyrazole ([11C] 1) and 4-[5-(4-methoxyphenyl)-3-trifluoromethyl-lH-pyrazol-1 -yljbenzenesulfonamide ([11C]2) for imaging COX-1 and COX-2 isoforms, respectively, by positron emission tomography. [11C]l and [11C]2 were synthesized in high radiochemical yields byO-[11C]methylation with [11C]methyl triflate in acetone containing an equivalent of NaOH as a base with respect to the phenolic precursors.In vivo evaluation in rats bearing AH109A hepatoma demonstrated minimal specific binding of [11C]1 to COX-1 in peripheral organs, such as the spleen and small intestine. Carrier-saturable uptake of [11C]2 was found in the spleen, but COX-2-specific binding of [101C]2 was not identifiable in the brain, AH109A hepatoma or other peripheral organs, althoughex vivo autoradiography showed regionally different distribution in the brain and AH 109A. The results suggest that neither [11C]1 nor [11C]2 is a suitable radioligand forin vivo biomarkers of COX enzymes, mainly because of marked non-specific binding.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Smith WL, Marnett LJ, Dewitt DL. Prostaglandin and thromboxane biosynthesis.Pharmacol Ther 1991; 49:153–179.
Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding Prostaglandin synthase is regulated by mRNA splicing.Proc Natl Acad Sci USA 1991; 88: 2692–2696.
Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of Prostaglandin H2 synthase (cyclooxygenase) in human monocytes.J Biol Chem 1990; 265: 16737–16740.
Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS 10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel Prostaglandin syn-thase/cyclooxygenase homologue.J Biol Chem 1991; 266: 12866–12872.
Hla T, Neilson K. Human cyclooxygenase-2 cDNA.Proc Natl Acad Sci USA 1992; 89: 7384–7388.
Goppelt-Struebe M. Regulation of Prostaglandin endoper-oxide synthase (cyclooxygenase) isozyme expression.Prostaglandins Leukot Essent Fatty Acids 1995; 52: 213–222.
Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits Prostaglandin G/H synthase/cyclooxygenase (COX-2) activityin vitro.Prostaglandins 1994; 47: 55–59.
Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, et al. Mechanism of selective inhibition of the inducible isoform of Prostaglandin G/H synthase.Proc Natl Acad Sci USA 1994; 91: 11202–11206.
Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.Proc Natl Acad Sci USA 1994; 91: 12013–12017.
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and ad-enocarcinomas.Gastroenterology 1994; 107: 1183–1188.
Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer.Cancer Res 1995; 55:3785–3789.
Kutchera W, Jones DA, Matsunami N, Groden J, Mclntyre TM, Zimmerman GA, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect.Proc Natl Acad Sci USA 1996; 93: 4816–41820.
Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristmaki A. Expression of cyclooxygenase-2 in human lung carcinoma.Cancer Res 1998; 58: 4997–5001.
Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.Cancer Res 1998; 58: 3761–3764.
Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells.Cancer Res 1996; 56: 4424–4429.
Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment.Trends Pharmacol Sci 2003; 24: 96–102.
Evans JF, Kargman SL. Cancer and cyclooxygenase-2 (COX-2) inhibition.Curr Pharm Des 2004; 10: 627–634.
Kaufmann WE, Andreasson KI, Isakson PC, Worley PF. Cyclooxygenases and the central nervous system.Prostaglandins 1997; 54: 601–624.
Yermakova A, O’Banion MK. Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders.Curr Pharm Des 2000; 6: 1755–1776.
Kam PCA, See AUL. Cyclo-oxygenase isoenzymes: physiological and pharmacological role.Anaesthesia 2000; 55: 442–449.
Okamoto T, Hino O. Expression of cyclooxygenase-1 and-2 mRNA in rat tissues: tissue-specific difference in the expression of the basal level of mRNA.Int J Mol Med 2000; 6: 455–457.
Yamagata K, Andreasson KI, Kaufman WE, Barnes CA, Worsley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons.Neuron 1993; 11: 371–386.
Holtz ML, Kindy MS, Craddock S, Moore RW, Pettigrew LC. Induction of PGH synthase andc-fos mRNA during early reperfusion of ischemic rat brain.Mol Brain Res 1996; 35: 339–343.
Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-lH-pyrazol-l-yl]benzenesulfonamide (SC-58635, celecoxib).J Med Chem 1997; 40: 1347–1365.
Prasit P, Wang Z, Brideau C, Chan CC, Charleson S,Cromlish W, et al. The discovery of rofecoxib, [MK 966, VIOXX, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)- furanone], an orally active cyclooxygenase-2 inhibitor.Bioorg Med Chem Lett 1999; 9: 1773–1778.
McCarthy TJ, Sheriff AU, Graneto MJ, Talley JJ, Welch MJ. Radiosynthesis,in vitro validation, andin vivo evaluation of18F-labeled COX-1 and COX-2 inhibitors.J Nucl Med 2002; 43: 117–124.
ae Vries EFJ, van Waarde A, Buursma AR, Vaalburg W. Synthesis andin vivo evaluation of18F-desbromo-Dup-697 as a PET tracer for cyclooxygenase-2 expression.J Nucl Med 2003; 44: 1700–1706.
Leblanc Y, Gauthier JY, Ethier D, Guay J, Mancini J, Riendeau D, et al. Synthesis and biological evaluation of 2,3-diarylthiophenes as selective COX-2 and COX-1 inhibitors.Bioorg Med Chem Lett 1995; 5: 2123–2128.
Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation.Proc Natl Acad Sci USA 1998; 95: 13313–13318.
Tanaka A, Hase S, Miyazawa T, Takeuchi K. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage.J Pharmacol Exp Ther 2002; 300: 754–761.
Ishiwata K, Kawamura K, Wang WF, Furumoto S, Kubota K, Pascali C, et al. Evaluation of O-[11C]methyl-l-tyrosine and O-[18F]fluoromethyl-l-tyrosine as tumor imaging tracers by PET.Nucl Med Biol 2004; 31: 191–198.
Ishiwata K, Seki H, Ishii K, Ishii S, Nozaki T, Senda M. Synthesis andin vivo evaluation of [11C]semotiadil, a benzothiazine calcium antagonist.Appl Radiat hot 1994; 45: 439–443.
Kawamura K, Ishiwata K. Improved synthesis of [11C]SA4503, [11C]MPDX and [11CJTMSX by use of [11C]methyl triflate.Ann Nucl Med 2004; 18: 165–168.
Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase.Biochem J 1995; 305: 479–484.
Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, et al. HER2 overexpression increases sensitivity to Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.Cancer Res 2005; 65: 4253–4260.
Någren K, Halldin C. Methylation of amide and thiol functions with [11C]methyl triflate, as exemplified by [11C]NMSP, [11C]flumazenil and [11C]methionine.J Label Compd Radiopharm 1998; 41: 831–841.
Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain.J Comp Neurol 1995; 355: 296–315.
Paulson SK, Kaprak TA, Gresk CJ, Fast DM, Baratta MT, Burton EG, et al. Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human.Biopharm Drug Dispos 1999; 20: 293–299.
Clark DE.In silico prediction of blood-brain barrier permeation.Drug Discov Today 2003; 8: 927–933.
Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.Nature 1996; 384: 644–648.
Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.J Med Chem 2004; 47: 550–557.
About this article
Cite this article
Fujisaki, Y., Kawamura, K., Wang, W. et al. Radiosynthesis andin vivo evaluation of11C-Iabeled 1,5-diarylpyrazole derivatives for mapping cyclooxygenases. Ann Nucl Med 19, 617 (2005). https://doi.org/10.1007/BF02985057
- cyclooxygenase inhibitor
- tissue distribution